Contents

TDM Journal Club

281 Pharmacogenomic Predictors of Neonatal Abstinence Syndrome: Correlation With Length of Stay
Lauren E. Kelly, Dave Knoppert, and Gideon Koren

283 TDM Journal Club: Safety and Immunogenicity of Tetanus Diphtheria and Acellular Pertussis Immunization During Pregnancy
Tom Leibson, Maude St-Onge, and Gideon Koren

Grand Round

285 Increased Levetiracetam Clearance and Breakthrough Seizure in a Pregnant Patient Successfully Handled by Intensive Therapeutic Drug Monitoring
Alberto M. Cappellari, Dario Cattaneo, Emilio Clementi, and Alessandra Kustermann

Original Articles

288 Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus
Henrike Bruckmuller, Anneke Nina Werk, Lutz Renders, Thorsten Feldkamp, Martin Tepel, Christoffer Borst, Amke Caliebe, Ulrich Kunzendorf, and Ingolf Cascorbi

(continued next page)
## Contents (continued)

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>296</td>
<td>Long-Term Cross-Validation of Everolimus Therapeutic Drug Monitoring Assays: The Zortracker Study</td>
<td>Björn Schniedewind, Stefanie Niederlechner, Jeffrey L. Galinkin, Kamisha L. Johnson-Davis, Uwe Christians, and Eric J. Meyer</td>
</tr>
<tr>
<td>304</td>
<td>Limited Sampling Strategy for Predicting Area Under the Concentration–Time Curve for Mycophenolic Acid in Chinese Adults Receiving Mycophenolate Mofetil and Tacrolimus Early After Renal Transplantation</td>
<td>Wene Cai, Changqing Ye, Xuyong Sun, Ke Qin, Yinhong Qin, Donghai Zhao, Fengfu Wu, Yun Hu, Haibin Li, and Luoqiao Tan</td>
</tr>
<tr>
<td>311</td>
<td>A Comparison of the Immunochemical Methods, PETINIA and EMIT, With That of HPLC-UV for the Routine Monitoring of Mycophenolic Acid in Heart Transplant Patients</td>
<td>Pawel K. Kunicki, Tomasz Pawiński, Aleksandra Boczek, Joanna Waś, and Magdalena Bodnar-Broniarczyk</td>
</tr>
<tr>
<td>319</td>
<td>High-Throughput Validated Method for the Quantitation of Busulfan in Plasma Using Ultrafast SPE-MS/MS</td>
<td>Darlington Danso, Paul J. Jannetto, Robert Enger, and Loralie J. Langman</td>
</tr>
<tr>
<td>325</td>
<td>Isotope-Dilution Gas Chromatography–Mass Spectrometry Method for the Analysis of Hydroxyurea</td>
<td>Uttam Garg, David Scott, Clint Frazee, Gregory Kearns, and Kathleen Neville</td>
</tr>
<tr>
<td>331</td>
<td>Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib: A Pharmacokinetic Feasibility Study</td>
<td>Djoekte de Wit, Nielka P. van Erp, Jan den Hartigh, Ron Wolterbeek, Margret den Hollander-van Deursen, Mariëtte Labots, Henk-Jan Guchelaar, Henk M. Verheul, and Hans Gelderblom</td>
</tr>
<tr>
<td>339</td>
<td>Sedative-Hypnotics Are Widely Abused by Drivers Apprehended for Driving Under the Influence of Drugs</td>
<td>Pirkko Kriikku, Hannes Hurme, Lars Wilhelm, Janne Rintatalo, Jukka Hurme, Jan Kramer, and Ilkka Ojanperä</td>
</tr>
<tr>
<td>347</td>
<td>Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation</td>
<td>Ozgur Yorbik, Caner Mutlu, Selma Ozilhan, Gul Eryilmaz, Nuket Isiten, Serdar Alparslan, and Esra Saglam</td>
</tr>
<tr>
<td>353</td>
<td>Therapeutic Drug Monitoring for Patients With Alzheimer Dementia to Improve Treatment With Donepezil</td>
<td>Guadrun Hefner, Anne Brueckner, Christoph Hiemke, and Andreas Fellgiebel</td>
</tr>
</tbody>
</table>

(continued next page)
Contents (continued)

362 Pharmacokinetic and Pharmacodynamic Evaluation of a Nanotechnological Topical Formulation of Lidocaine/Prilocaine (Nanorap) in Healthy Volunteers
Thiago Gagliano-Jucá, Maira R. Castelli, Gustavo D. Mendes, André M. M. Arruda, Lu Shi Chen, Marco A. de Oliveira, Sérgio F. Costa, Antíbal Gil Lopes, Wanderley de Souza, and Gilberto De Nucci

369 Functional Study of Haplotypes in UGT1A1 Promoter to Find a Novel Genetic Variant Leading to Reduced Gene Expression
Hee Jung Shin, Jason Yongha Kim, Hyun Sub Cheong, Han Sung Na, Hyoung Doo Shin, and Myeon Woo Chung

375 Measurement of Non–Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using HepTest-STAT Coagulation Method
Shanshan Da, Job Harenberg, Sandra Krämer, Roland Krämer, Martin Wehling, and Christel Weiss

381 Improvement and Validation of a High-Performance Liquid Chromatography in Tandem Mass Spectrometry Method for Monitoring of Omeprazole in Plasma
Aneta Wojnicz, Ana Isabel Gil Garcia, Manuel Román-Martínez, Dolores Ochoa-Mazarro, Francisco Abad-Santos, and Ana Ruíz-Nuño

389 Describing Assay Precision—Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance
Roger W. Jelliffe, Alan Schumitzky, David Bayard, Xiaowei Fu, and Michael Neely

Short Communications

395 Age-Dependent Changes in Sirolimus Metabolite Formation in Patients With Neurofibromatosis Type 1
Chie Emoto, Tsuyoshi Fukuda, Tomoyuki Mizuno, Shareen Cox, Björn Schniedewind, Uwe Christians, Brigitte C. Widemann, Michael J. Fisher, Brian Weiss, John Perentesis, and Alexander A. Vinks

400 Performance of the New RapidFire System for Therapeutic Monitoring of Immunosuppressants
Denis Grote-Koska, Stefan Czajkowski, and Korbinian Brand

405 Correlation Analysis Between Cotinine Hair Concentrations From Active Smokers and Nicotine Intake and Dependence
Marina Venzon Antunes, Cássia Franciele Rosa da Silva, Marcélia Andressa Finger, Christine Moore, and Rafael Linden

408 Decreased Escitalopram Concentrations Post–Roux-en-Y Gastric Bypass Surgery
Mark A. Marzinke, Athena K. Petrides, Kimberley Steele, Michael A. Schweitzer, Thomas H. Magnuson, Shauna P. Reinblatt, Janelle W. Coughlin, and William Clarke

(continued next page)
Contents (continued)

413 Validation of a Pediatric Population Pharmacokinetic Model for Vancomycin
Andrea Hahn, Robert W. French, Jr., Yuanshu Zou, and Alexander A. Vinks

Letters to the Editor

417 Paraprotein Interference in Immunoassays
Donald F. LeGatt and Trefor N. Higgins

417 Unexpected Overestimation of Methotrexate Plasma Concentrations: Importance of the Assay Implementation and Its Validation
Maaike Godefroid, Alain G. Verstraete, and Veronique Stove

---

Conversion Formula

Readers who want to convert drug concentrations to or from SI units may apply the following formulas.

To determine the conversion factor (CF): \[ CF \times \frac{1000}{MW} \]

To convert to SI units: \( \text{µg/mL} \times CF = (\mu\text{mol/L}) \)
To convert from SI units: \( (\mu\text{mol/L}) \div CF = (\mu\text{g/mL}) \)

Example: Phenytoin conversion

Conversion factor: \( \frac{1000}{MW} = 3.96 \)

Conversion: \( (\mu\text{g/mL}) \times 3.96 = (10 \mu\text{g/mL}) \times 3.96 = 39.6 \mu\text{mol/L} \)
\( (39.6 \mu\text{mol/L}) \div 3.96 = 10 \mu\text{g/mL} \)